您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > OR-1855
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
OR-1855
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
OR-1855图片
CAS NO:101328-85-2
包装与价格：
包装价格(元)
100mg电议
200mg电议
500mg电议

产品介绍
OR-1855 是 Levosimendan 的活性代谢产物，对人体肌层收缩力有影响。Levosimendan 是一种钙敏感性药物，用于治疗急性失代偿性充血性心力衰竭。
Cas No.101328-85-2
别名(R)-6-(4-氨基苯基)-4,5-二氢-5-甲基-3(2H)-哒嗪酮
Canonical SMILESO=C1C[C@@H](C)C(C2=CC=C(N)C=C2)=NN1
分子式C11H13N3O
分子量203.24
溶解度Soluble in DMSO
储存条件4°C, protect from light
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

OR-1855, an active metabolite of Levosimendan, has effect on human myometrial contractility. Levosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure[1][2].

[1]. Banfor PN, et al. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H238-48. [2]. Mark P. Hehir, et al. 487: OR-1855, a levosimendan metabolite with an effect on human myometrial contractility.December 2009Volume 201, Issue 6, Supplement, Pages S182-S183.